Commission appoints EFNA Vice-President, Cathalijne van Doorne, to Pharmacovigilance Risk Assessment Committee (PRAC)

The European Commission has appointed Cathalijne van Doorne, EFNA Vice-President, to the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA).
EFNA is pleased to announce that Cathalijne has been selected to act as the member representing patient organisations for three years, starting from March 1st 2019.

Cathalijne van Doorne

Share this article

Share this! Tweet this! Share this!